Pharmacy Prior Authorization

Similar documents
Circle Yes or No Y N. [If no, then no further questions.]

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Prior Authorization. Drug Name (select from list of drugs shown) Gilenya (fingolomid) Quantity Frequency Strength. Physician Name:

Circle Yes or No Y N. [If no, skip to question 8.] 2. Has the patient been compliant with therapy as verified by the prescriber?

2. Is the patient responding to medication? Y N

3. Have baseline A1c or fasting glucose, thyroid-stimulating hormone (TSH), and electrocardiography (EKG) been checked?

Pharmacy Prior Authorization

3. Does the patient meet ALL of the following requirements? Y N

2. Does the patient have a diagnosis of Crohn s disease? Y N

1. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?

2. Does the member have a diagnosis of central precocious puberty? Y N

Pharmacy Prior Authorization

2. Is this request for a preferred medication? Y N

Pharmacy Prior Authorization

For all requests for Multiple Sclerosis Medications all of the following criteria must be met:

3. Has the patient had a sustained improvement in Pain or Function (e.g. PEG scale with a 30 percent response from baseline)?

3. Has the member received the requested drug for less than 2 years? Y N

3. Does the patient continue to receive nutritional or psychological counseling? Y N

3. Has the member received the requested drug for less than 2 years? Y N

2. Does the patient have a diagnosis of giant cell arteritis (GCA)? Y N

3. Is the prescribed dose within the Food and Drug Administration (FDA)- approved dosing for giant cell arteritis?

2. Did the patient receive this medication during a recent hospitalization? Y N

2. Did the member receive this medication during a recent hospitalization? Y N

3. Has bone specific alkaline phosphatase level increased OR does the member have symptoms related to active Paget s?

2. Does the patient have a diagnosis of ulcerative colitis or Crohn s? Y N

2. Does the patient have a diagnosis of chronic idiopathic thrombocytopenic purpura (ITP)?

Pharmacy Prior Authorization

Pharmacy Prior Authorization

2. Is the patient responding to Remicade therapy? Y N

3. Does the member continue to receive nutritional or psychological counseling?

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

1. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Circle Yes or No Y N. [If yes, skip to question 29.] 2. Is the request for Sandostatin LAR? Y N. [If no, skip to question 5.] Prior Authorization

2. Does the patient have chronic urticaria? Y N

3. Does the patient have a diagnosis of rheumatoid arthritis (RA) with moderate to high disease activity?

2. Is therapy prescribed by, or in consultation with, a hematologist and/or oncologist?

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.

Please submit supporting medical documentation, notes and test results.

Circle Yes or No Y N. [If no, skip to question 7.] 2. Does the patient have a diagnosis of ulcerative colitis? Y N. [If no, skip to question 4.

3. Did the patient show evidence of remission by week 8 of Humira Y N therapy?

GILENYA (fingolimod) oral capsule

3. Has the patient shown improvement in signs and symptoms of the disease? Y N

APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM

Circle Yes or Y N. [Note: requests without this information will not be accepted.] [If no, then no further questions.

2. Has the patient had a response to treatment? Y N. 3. Does the patient have a diagnosis of rheumatoid arthritis (RA)? Y N

Pharmacy Prior Authorization

Circle Yes or No Y N. [If yes, skip to question 13 REAUTHORIZATION REQUESTS]

Pharmacy Prior Authorization

Circle Yes or No Y N. (Note: requests without this information will not be accepted.) [If no, then no further questions.]

[If yes, no further questions.]

2. Is the request for Alli, Xenical or Belviq? Y N. 3. Has the patient received 6 months or more of therapy? Y N

Pharmacy Prior Authorization

Circle Yes or No Y N. [If yes, skip to question 30.] 2. Is this request for a child? Y N. [If no, skip to question 20.]

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

Prior Authorization. Drug Name (select from list of drugs shown) Viekira Pak (ombitasv-paritaprev-ritonav-dasabuv) Quantity Frequency Strength

2. Has this plan authorized this medication in the past for this member (i.e., previous authorization is on file under this plan)?

MEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Multiple Sclerosis Agents

Circle Yes or No Y N. [If yes, no further questions.]

Medication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012

2. Is the request for Humatrope? Y N [If no, skip to question 6.]

Gilenya. Gilenya (fingolimod) Description

Gilenya. Gilenya (fingolimod) Description

GILENYA (fingolimod) oral capsule

Prior Authorization. Physician Name: Specialty: NPI Number: Physician Fax: Physician Phone: Physician Address: City, State, Zip:

Committee Approval Date: December 12, 2014 Next Review Date: December 2015

AMPYRA (dalfampridine) extended release oral tablet Dalfampridine ER oral tablet

Drug Name (specify drug) Quantity Frequency Strength

9/9/2016. Drug Name (select from list of drugs shown) Bunavail Buccal Film (buprenorphinenaloxone) Suboxone Sublingual Film (buprenorphine-naloxone)

Medication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013

AUBAGIO (teriflunomide) oral tablet

Gilenya. Gilenya (fingolimod) Description

Updates to the Alberta Human Services Drug Benefit Supplement

Drug Name (specify drug) Quantity Frequency Strength

Drug Name (specify drug) Quantity Frequency Strength

Ribavirin (Medicare Prior Authorization)

MULTIPLE SCLEROSIS - REVIEW AND UPDATE

Medical Policy An Independent Licensee of the Blue Cross and Blue Shield Association

Regulatory Status FDA-approved indication: Tecfidera is indicated for the treatment of patients with relapsing forms of multiple sclerosis (1).

Clinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.PHAR.258 Effective Date: Last Review Date: Line of Business: Medicaid

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Clinical Policy: Mitoxantrone (Novantrone) Reference Number: CP.CPA.334 Effective Date: Last Review Date: Line of Business: Commercial

TECFIDERA (dimethyl fumarate) oral capsule

Calcitonin Gene Related Peptide Receptor Inhibitors Prior Authorization Criteria:

See Important Reminder at the end of this policy for important regulatory and legal information.

PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day

Clinical Policy: Natalizumab (Tysabri) Reference Number: ERX.SPA.162 Effective Date:

Aubagio. Aubagio (teriflunomide) Description

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259 Effective Date: Last Review Date: Line of Business: Medicaid

Regulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of (1):

Regulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of:

Pediatric MS treatments: What do you start with, when do you switch?

DISCLAIMER FDA INDICATIONS INITIAL COVERAGE CRITERIA POSITION STATEMENT. Subject: Aubagio (teriflunomide) Original Effective Date: 10/30/2013

Prior Authorization Criteria Form This form applies to Paramount Commercial Members Only. Non-Preferred Growth Hormone Products

Transcription:

Pharmacy Prior Authorization AETA BETTER HEALTH VIRGIIA Multiple Sclerosis Agents (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Aetna Better Health Virginia at 1-855-799-2553. When conditions are met, we will authorize the coverage of Multiple Sclerosis Agents (Medicaid). Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise. Drug ame (please circle) Drug, please specify Quantity Frequency Strength Route of Administration Expected Length of therapy Patient Information Patient ame: Patient ID: Patient Group o.: Patient DOB: Patient Phone: Prescribing Physician Physician ame: Specialty: PI umber: Physician Fax: Physician Phone: Physician Address: City, State, Zip: Diagnosis: ICD Code: Please circle the appropriate answer for each question. Question 1. Is the requested drug prescribed by or in consultation with a neurologist? Circle es or o 2. Has this plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)? [If no, skip to question 15.] 3. Is the patient having a positive clinical response to the medication? 4. Is the renewal for Tysabri? Reference umber: C6578 A / Effective Date: 02/08/2017 1

Circle es or o 5. Is the renewal for Aubagio? [If no, skip to question 7.] 6. Has the patient had a CBC, LFT s, and bilirubin that are within normal limits since starting Aubagio? Please document lab results and date (or submit labs with request): [o further questions.] 7. Is the renewal for Tecfidera? [If no, skip to question 9.] 8. Has the patient had a CBC that was within normal limits since starting Tecfidera? Please document lab result and date (or submit labs with request): [o further questions.] 9. Is the renewal for Gilenya? [If no, skip to question 12.] 10. Has the patient had a CBC, LFT s, and bilirubin that are within normal limits since starting Gilenya? Please document lab results and date (or submit labs with request): 11. Has the patient had a normal EKG and ophthalmic examination since starting Gilenya? Please document date of EKG and eye exam (or submit clinical documentation with request): [o further questions.] 12. Is the renewal for Lemtrada? [If no, skip to question 14.] 13. Has the patient received more than 2 years of treatment with Lemtrada? If yes, please provide rationale for continued treatment: [o further questions.] 14. Is the renewal for mitoxantrone? [If yes, skip to question 21.] Reference umber: C6578 A / Effective Date: 02/08/2017 2

Circle es or o 15. Is this a request for mitoxantrone? [If no, skip to question 25.] 16. Does the patient have a diagnosis of relapsing-remitting multiple sclerosis (RRMS)? [If no, skip to question 18.] 17. Has the patient had an inadequate response, intolerable side effects, or has a contraindication to 2 formulary agents, one of which must be a formulary interferon or glatiramer acetate agent? (see formulary for a list of preferred agents) List medications tried and description of failure: [If yes, skip to question 19.] 18. Does the patient have a diagnosis of secondary (chronic) progressive MS (SPMS) or progressive relapsing MS (PRMS)? 19. Will all other multiple sclerosis medications (not including Ampyra) be discontinued before starting mitoxantrone? 20. Is the patient at least 18 years old? 21. Has the patient received a cumulative lifetime dose of 140mg/m2? 22. Has the patient had an ECHOcardiogram and a CBC within the past 6 months? 23. Was the LVEF (left ventricular ejection fraction) less than 50%? 24. Did the CBC show an AC less than 1500 cells/mm3? [o further questions.] 25. Does the patient have a diagnosis of relapsing-remitting multiple sclerosis? [If yes, skip to question 28.] 26. Is this a request for Copaxone, Avonex, Betaseron, or Extavia for a diagnosis of clinically isolated syndrome suggestive of multiple sclerosis (i.e. persons who have experienced a first clinical episode and have magnetic resonance imaging (MRI) features consistent with multiple sclerosis)? Reference umber: C6578 A / Effective Date: 02/08/2017 3

Circle es or o 27.Is the request for Extavia? 28.Is the request for a formulary preferred injectable agent? (refer to formulary for a list of preferred agents) 29.Is the request for Aubagio? [If no, skip to question 31.] 30.Have all of the following labs been completed within the last 6 months: A) Complete blood count (CBC) that is within normal limits, B) Liver function tests (LFTs) and bilirubin levels that are within normal limits, C) egative pregnancy test if female, and D) egative tuberculin skin test for latent TB 31.Is the request for Gilenya? [If no, skip to question 35.] 32.Have all of the following labs been completed within the last 6 months: A) Complete blood count (CBC) that is within normal limits, B) Liver function tests (LFTs) and bilirubin levels that are within normal limits, C) egative pregnancy test if female, D) EKG evaluation that is within normal limits, and E) ormal ophthalmic examination 33.Does the patient have a confirmed history of chicken pox OR vaccination for the varicella zoster virus OR lab testing confirming varicella antibodies? 34.Has the patient experienced any of the following within the last 6 months: A) myocardial infarction, B) unstable angina, C) stroke or TIA, or D) decompensated heart failure requiring hospitalization or Class III/IV heart failure [If no, skip to question 42.] 35.Is the request for Tecfidera? [If no, skip to question 37.] 36.Has the patient had a normal complete blood count within the past 6 months? Reference umber: C6578 A / Effective Date: 02/08/2017 4

Circle es or o 37. Is the request for Lemtrada? [If no, skip to question 40.] 38. Does the patient have HIV infection? [If yes, no further questions.] 39. Has the patient already received a 2 year course of therapy with Lemtrada? [If yes, no further questions.] [If no, skip to question 41.] 40. Is the request for Tysabri? [If no, then no further questions] 41. Has the patient had an inadequate response, intolerable side effects, or has a contraindication to 2 formulary agents, one of which must be a formulary interferon or glatiramer acetate agent? (see formulary for a list of preferred agents) List medications tried and description of failure: 42. Will all other multiple sclerosis medications (not including Ampyra) be discontinued before starting the requested medication? [If no, then no further questions] 43. Is the patient at least 18 years old (or 17 years old for Lemtrada)? Comments: I affirm that the information given on this form is true and accurate as of this date. Prescriber (Or Authorized) Signature Prescriber (Or Authorized) Signature Date Date Reference umber: C6578 A / Effective Date: 02/08/2017 5